NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1895
+0.0125 (+7.0621%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1770
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume1,138,520
Market Cap78.579M
Beta2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.3940
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 months ago

    Independent Research on Trending Growth Companies: Northwest Biotherapeutics and Sanuwave Health

    NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Northwest Biotherapeutics, Inc. (OTCQB: NWBO) and Sanuwave Health ...

  • NW Bio Congratulates Cognate BioServices On Its Management Buyout
    PR Newswire2 months ago

    NW Bio Congratulates Cognate BioServices On Its Management Buyout

    BETHESDA, Md., Feb. 20, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, congratulated Cognate BioServices, the contract manufacturer of NWBio's DCVax® products, on the Management Buyout of Cognate supported by global institutional investors, which Cognate announced today. Following this transaction, neither Linda Powers nor any Toucan Capital related entities have any ownership interest in Cognate or any role on Cognate's Board. More information can be found in a Cognate press release at https://www.businesswire.com/news/home/20180220006077/en.

  • PR Newswire4 months ago

    NW Bio Announces Regulation D Offering for Accredited Investors

    BETHESDA, Md., Dec. 19, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering  to accredited investors.  The Offering will remain open for execution of subscription agreements until 5:30 pm EST on Wednesday, December 27, 2017, and the closing is expected to take place on Friday, December 29, 2017.

  • NW Bio Announces Completion of $12 Million Financing
    PR Newswire5 months ago

    NW Bio Announces Completion of $12 Million Financing

    BETHESDA, Md., Dec. 4, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations.  The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and Warrants.  The Preferred Stock will be convertible into common stock, but only when common stock is available or after 6 months following issuance.  The Warrants will be exercisable for common stock, but only when common stock is available.  The shares are registered, but are subject to restrictions under which they may not be conveyed or traded until a shareholder vote takes place, pursuant to which the number of authorized shares is increased.  The shares are also subject to a voting agreement, under which the investors have agreed to vote in support of such increase in authorized shares.

  • NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
    PR Newswire6 months ago

    NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

    BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.

  • NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
    PR Newswire6 months ago

    NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

    BETHESDA, Md., Oct. 25, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.

  • NW BIO Announces Registered Direct Offering Of $1.75 Million
    PR Newswire7 months ago

    NW BIO Announces Registered Direct Offering Of $1.75 Million

    BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share.  Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.

  • Capital Cube8 months ago

    ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
    PR Newswire8 months ago

    DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

    DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW ...

  • NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    PR Newswire10 months ago

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds

    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondholders entered into in March. The convertible debt issued in the transaction has a 3-year maturity.

  • Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today
    PR Newswire11 months ago

    Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

    BETHESDA, Md., June 5, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical trial programs. Dr. Bosch's presentation will include updates on the Company's Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer, as well as the Information Arm related to the GBM trial, and the Company's Phase I/II Trial of DCVax-Direct for inoperable solid tumors.

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube11 months ago

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)